Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27637408 | 0.78 | ELANE (0.34) | ELANE | |
| SCHEMBL1141482 | 0.75 | AKT1 (0.38) | ELANE | |
| SCHEMBL11911441 | 0.73 | MAP2K4 (0.40) | ELANE | |
| SCHEMBL1141936 | 0.70 | MAP2K4 (0.31) | — | |
| SCHEMBL1141929 | 0.70 | ELANE (0.33) | ELANE | |
| SCHEMBL27637417 | 0.70 | MAP2K4 (0.38) | ELANE | |
| SCHEMBL27637471 | 0.69 | MAP2K4 (0.33) | ELANE | |
| SCHEMBL1141597 | 0.68 | MAP2K4 (0.36) | ELANE | |
| SCHEMBL1141491 | 0.68 | GRM2 (0.43) | — | |
| SCHEMBL27637644 | 0.68 | MAP2K4 (0.36) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468729-B1 | Novel indazole derivative | UBE INDUSTRIES (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-8232308-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| EP-2468729-A1 | Novel indazole derivative | UBE INDUSTRIES, LTD. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-7855222-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1679308-A1 | NOVEL INDAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, RHOT2 | ELANE 265/4885 |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, ROCK2 | ELANE 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.